Zheng Quan Ri Bao·2025-08-01 08:09Core Viewpoint - Eli Lilly's MuFenda® (Tirzepatide injection multi-dose pen) has been launched online on JD Health, marking a significant advancement in the treatment of type 2 diabetes and long-term weight management, leveraging its unique dual-action mechanism and efficacy [1][2]. Group 1: Product Launch and Features - MuFenda® is the first and only GIP/GLP-1 receptor agonist approved for type 2 diabetes and long-term weight management globally [1]. - The new multi-dose pen design incorporates an innovative "4-dose integration," allowing patients to use one dose per week, fulfilling a month's treatment needs [1]. - The pen can be stored at room temperature (not exceeding 30°C) for 30 days after the first use, enhancing convenience for patients [1]. Group 2: Patient Experience and Accessibility - The multi-dose pen is designed for ease of use, with simple steps for loading the needle, expelling air, adjusting the dose, and injecting, which improves patient comfort [2]. - JD Health expressed enthusiasm for collaborating with Eli Lilly to introduce MuFenda® multi-dose pen, aiming to enhance the purchasing experience for patients [2]. - The launch on JD Health is expected to benefit more patients with type 2 diabetes and obesity, promoting healthier lifestyles [2].